Has Karan Omidvari, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,067 in general payments to Karan Omidvari, MD across 189 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Karan Omidvari, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Karan Omidvari, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Karan Omidvari, MD

Critical Care Medicine · Hackensack, NJNPI 1962474742

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.8% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by AstraZeneca at 27.9% of the total. 2025 is the largest year on record at $2,973, more than ten times the $61 reported in 2020.

$4,067in general payments, 2019–2025

Across 189 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$1K
GSK$488
Insmed, Inc.$239
Sanofi$230
Amgen$223
Viatris Specialty LLC$205
plus $2K from 30 others

What the payments were for

Consulting fees$612%
Food & beverage$3,81394%
Education$1935%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	13	$1,133
GSK	31	$488
Insmed, Inc.	24	$239
Sanofi	13	$230
Amgen	22	$223
Viatris Specialty LLC	10	$205
United Therapeutics Corporation	10	$145
Verona Pharma, Inc.	10	$144
Actelion Pharmaceuticals US, Inc.	4	$135
Sanofi-aventis U.S. LLC	1	$98
Intuitive Surgical	1	$89
Merck	5	$87
Boehringer Ingelheim	5	$86
Grifols USA, LLC	4	$71
ADMA Biomanufacturing LLC	3	$61
Philips North America LLC	3	$55
Inquis Medical, Inc.	2	$55
Harmony Biosciences LLC	3	$53
Mallinckrodt Hospital Products Inc.	3	$51
Mindray DS USA, Inc.	1	$47
Abiomed	2	$41
Regeneron Healthcare Solutions, Inc.	2	$36
Pfizer	2	$32
Mylan Specialty L.p.	2	$32
AbbVie	2	$31
Medtronic	1	$26
Baxter Healthcare	1	$23
Advanced Respiratory, Inc	1	$23
Electromed, Inc.	1	$20
Takeda Pharmaceuticals U.S.A., Inc.	1	$18
ANI Pharmaceuticals, Inc.	1	$16
Vifor Pharma, Inc.	1	$15
Teva Pharmaceuticals USA, Inc.	1	$15
Paratek Pharmaceuticals, Inc.	1	$15
Avadel CNS Pharmaceuticals, LLC	1	$15
Nestle Healthcare Nutrition Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,067 in reported general payments places this provider in the 80th percentile of 254 critical care medicine providers in New Jersey.

See all critical care medicine providers in New Jersey →

Medicare billing

Part B allowed, 2024

$256,404

Medicare patients

302

Services billed

1,315

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other critical care medicine in Hackensack

Eric TellerHackensack$217K
Raghad SaidHackensack$48K
Keith RoseHackensack$13K
Sean McKayHackensack$5K
Eugene BunnellHackensack$3K
Ronak ShahHackensack$2K
Fariborz RezaiLivingston$2.3M
R Phillip DellingerCamden$74K
Neha VagadiaMarlton$31K
Mark RamzyWest Orange$31K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →